Cristin-resultat-ID: 1812163
Sist endret: 8. september 2020, 13:24
NVI-rapporteringsår: 2020
Resultat
Vitenskapelig oversiktsartikkel/review
2020

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Bidragsytere:
  • Tobias Täger
  • Dan Atar
  • Stefan Agewall
  • Hugo A. Katus
  • Morten Grundtvig
  • John G.F. Cleland
  • mfl.

Tidsskrift

Heart Failure Reviews
ISSN 1382-4147
e-ISSN 1573-7322
NVI-nivå 1

Om resultatet

Vitenskapelig oversiktsartikkel/review
Publiseringsår: 2020
Publisert online: 2020
Sider: 1 - 15
Open Access

Importkilder

Scopus-ID: 2-s2.0-85084070141

Beskrivelse Beskrivelse

Tittel

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Sammendrag

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D). The comparative efficacy of individual SGLT2i remains unclear. We searched PubMed, www.clinicaltrials.gov and the Cochrane Central Register of Controlled Trials for randomised controlled trials exploring the use of canagliflozin, dapagliflozin, empagliflozin or ertugliflozin in patients with T2D. Comparators included placebo or any other active treatment. The primary endpoint was all-cause mortality. Secondary endpoints were cardiovascular mortality and worsening heart failure (HF). Evidence was synthesised using network meta-analysis (NMA). Sixty-four trials reporting on 74,874 patients were included. The overall quality of evidence was high. When compared with placebo, empagliflozin and canagliflozin improved all three endpoints, whereas dapagliflozin improved worsening HF. When compared with other SGLT2i, empagliflozin was superior for all-cause and cardiovascular mortality reduction. Empagliflozin, canagliflozin and dapagliflozin had similar effects on improving worsening HF. Ertugliflozin had no effect on any of the three endpoints investigated. Sensitivity analyses including extension periods of trials or excluding studies with a treatment duration of

Bidragsytere

Tobias Täger

  • Tilknyttet:
    Forfatter
    ved Universitätsklinikum Heidelberg
Aktiv cristin-person

Dan Atar

  • Tilknyttet:
    Forfatter
    ved Hjertemedisinsk avdeling ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Hjertemedisinsk avdeling ved Universitetet i Oslo

Stefan Agewall

  • Tilknyttet:
    Forfatter
    ved Hjertemedisinsk avdeling ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Hjertemedisinsk avdeling ved Oslo universitetssykehus HF

Hugo A. Katus

  • Tilknyttet:
    Forfatter
    ved Universitätsklinikum Heidelberg

Morten Grundtvig

  • Tilknyttet:
    Forfatter
    ved Div Gjøvik/Lillehammer ved Sykehuset Innlandet HF
1 - 5 av 9 | Neste | Siste »